[The outlook for the creation of a bank of cryopreserved cord blood for clinical use].

Appraisal of morphological and functional features of cord blood cells involving identification of precursor cells marked with specific monoclonal antibodies makes it possible to regard cord blood as biologically valuable hemopoietic tissue with a high repopulation potential. Studies aimed at developing optimal conditions of cryopreservation allow the stocks of biologically valuable tissue to be built up.

[Preclinical trials of polyplatillen, the antitumor activity of a complex platinum compound with DNA on a leukemia P388 model in a HEp-2 cell culture (1)].

The authors studied the antitumour activity of a new complex platinum compound (DDP-DNA) in mice with leukemia P-388 and in cell culture. DDP-DNA was introduced intraperitoneally 24 hours after inoculation of 2 x 10(6) tumour cells. It was established that by its antitumour activity DDP-DNA was not inferior then DDP.

[Toxico-pharmacologic and genetic study of a novel cryopreserving solution for bone marrow cells].

Physico-chemical, biological and genetic properties of a cryopreserving solution for myelokaryocytes were studied. It was shown that the solution is harmless for the body, stable during storage, it produces no teratogenic or mutagenic effects, it should not be washed out before bone marrow cell administration to the recipient.

[Study of tissue coagulation factors of native and cryopreserved bone marrow].

Status of thromboplastin, antiheparin and antithrombin characteristics of the native and cryopreserved bone marrow was studied experimentally on 12 rabbits. It is found that both the native and cryopreserved bone marrow possesses a pronounced and dilution resistant thromboplastin activity, whereas antithrombin and heparin activities were statistically unauthentic. In that connection the bone marrow injected into blood circulation may have different effects depending on the initial state of the recipient blood coagulation.